For the Inventor, By the Inventor

Enter assignee name

Bethesda, MD, United States of America

Northwest Biotherapeutics, Inc.

Calculating rank

USPTO Granted Patents = 16

% Expired Patents = 50.0

CIPO Patents = 5

EPO Patents = 15

Trademarks = 2

Forward Citations = 133

Loading Chart...

Loading Chart...

16 inventors (with patents filed for the assignee):

Alton L Boynton (9 out of 17 patents)

Marnix L Bosch (8 out of 8 patents)

Gerald P Murphy (5 out of 18 patents)

4. Anil Sehgal (5 out of 6 patents)

5. Benjamin A Tjoa (4 out of 5 patents)

6. Patricia A Lodge (3 out of 3 patents)

7. Paul C Harris (2 out of 15 patents)

8. Eric H Holmes (2 out of 19 patents)

9. Steven J Monahan (2 out of 2 patents)

10. Allen Turner (2 out of 2 patents)

11. Julie A McEarchern (1 out of 13 patents)

12. William T Tino (1 out of 17 patents)

13. Paul G Hugenholtz (1 out of 1 patent)

14. Yaling Zhou (1 out of 1 patent)

15. Anne L Sherwood (1 out of 3 patents)

16 patents: Sort by Forward Citations

1. 11827903 - Generation of dendritic cells from monocytic dendritic precursor cells with GM-CSF in the absence of additional cytokines (2023-11-28),

2. 11124768 - Optimally activated dendritic cells that induce an improved or increased anti-tumor immune response (2021-09-21),

3. 10731130 - Generation of dendritic cells from monocytic dendritic precursor cells with GM-CSF in the absence of additional cytokines (2020-08-04),

4. 9566294 - Therapeutic and diagnostic applications based on the role of the CXCR-4 gene in tumorigenesis (2017-02-14),

5. 9102917 - Generation of dendritic cells from monocytic dendritic precursor cells with GM-CSF in the absence of additional cytokines (2015-08-11),

6. 8518636 - Tangential flow filtration devices and methods for leukocyte enrichment (2013-08-27),

7. 8409566 - Therapeutic and diagnostic applications based on the role of the CXCR-4 gene in tumorigenesis (2013-04-02),

8. 8389278 - Generation of dendritic cells from monocytic dendritic precursor cells with GM-CSF in the absence of additional cytokines (2013-03-05),

9. 7790039 - Tangential flow filtration devices and methods for stem cell enrichment (2010-09-07),

10. 7695627 - Tangential flow filtration devices and methods for leukocyte enrichment (2010-04-13),

11. 7087715 - Human paris-1 antigen and nucleic acids: diagnostic and therapeutic uses (2006-08-08),

12. 6936448 - Nucleic acids and proteins of a rat ganglioside GM1-specific α1-2fucosyltransferase and uses thereof (2005-08-30),

13. 6863887 - Therapeutic and diagnostic applications based on the role of the CXCR-4 gene in tumorigenesis (2005-03-08),

14. 6150508 - Monoclonal antibodies specific for the extracellular domain of (2000-11-21),

15. 5990294 - Nucleotide and amino acid sequences of C4-2, a tumor suppressor gene, (1999-11-23),

Company Overview

Northwest Biotherapeutics, Inc. is a biotechnology company based in Bethesda, Maryland, specializing in the development of innovative cancer immunotherapy treatments. The company focuses on harnessing the body’s immune system to target and destroy cancer cells, particularly through its proprietary dendritic cell therapy platform. This approach aims to provide personalized treatment options for patients with various types of cancer, emphasizing safety and efficacy in therapeutic outcomes.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

16 Patents

#20 in Bethesda, MD

#276 in Maryland

#19,935 in US

#37,868 in the World

Bethesda, MD, United States of America

Northwest Biotherapeutics, Inc.

Forward Citations = 133

16 inventors:

Alton L Boynton (9 out of 17 patents)

Marnix L Bosch (8 out of 8 patents)

Gerald P Murphy (5 out of 18 patents)

4. Anil Sehgal (5 out of 6 patents)

5. Benjamin A Tjoa (4 out of 5 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Northwest Biotherapeutics, Inc.. Retrieved from https://idiyas.com/company/northwest-biotherapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…